Swedish Orphan Biovitrum AB (CHIX:SOBIS) Interest Expense : kr-1,150 Mil (TTM As of Mar. 2025)

View and export this data going back to 2012. Start your Free Trial

What is Swedish Orphan Biovitrum AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Swedish Orphan Biovitrum AB's interest expense for the three months ended in Mar. 2025 was kr -262 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was kr-1,150 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Swedish Orphan Biovitrum AB's Operating Income for the three months ended in Mar. 2025 was kr 1,358 Mil. Swedish Orphan Biovitrum AB's Interest Expense for the three months ended in Mar. 2025 was kr -262 Mil. Swedish Orphan Biovitrum AB's Interest Coverage for the quarter that ended in Mar. 2025 was 5.18. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Swedish Orphan Biovitrum AB Interest Expense Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Interest Expense Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-454.00

-419.00

-458.00

-1,111.00

-1,219.00

Swedish Orphan Biovitrum AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-331.00	-337.00	-326.00	-225.00	-262.00

Swedish Orphan Biovitrum AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1,150 Mil.

Swedish Orphan Biovitrum AB (CHIX:SOBIs) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Swedish Orphan Biovitrum AB's Interest Expense for the three months ended in Mar. 2025 was kr-262 Mil. Its Operating Income for the three months ended in Mar. 2025 was kr1,358 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was kr10,009 Mil.

Swedish Orphan Biovitrum AB's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2025 )	/	Interest Expense (Q: Mar. 2025 )
	=	-1	*	1358	/	-262
	=	5.18

The higher the ratio, the stronger the company's financial strength is.

Swedish Orphan Biovitrum AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (CHIX:SOBIs) » Definitions » Interest Expense

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBI:Sweden 1SOBI:Italy 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB Headlines

No Headlines